Background. Chronic kidney disease (CKD) is a common complication of diabetes, and requires long-term medical care. However, besides the blood glucose level, no reliable method is currently available to link the quality of care and the development of CKD. We therefore developed a long-term quality-ofcare score for predicting the occurrence of CKD in patients with type 2 diabetes. Methods. In this retrospective cohort study, using Taiwan's Longitudinal Cohort of Diabetes Patients Database and the medical records in a medical center, we identified incident patients with type 2 diabetes during 1999-2003 and followed them until 2011. A quality-of-care score (from 0 to 8) was calculated according to process indicators (frequencies of HbA1c and lipid profile testing and urine, foot, and retinal examinations), intermediate outcome indicators (low-density lipoprotein, blood pressure, and HbA1c) and comorbidity of hypertension. We used Cox regression models to evaluate the association between the score and the incidence of CKD. Results. Of the 4754 patients enrolled, 1407 developed CKD after a mean follow-up of 9.06 years. Compared with the risk of developing a CKD event in patients with scores 2, the risk was 69% lower in those with quality-of-care scores !5 (hazard ratio [HR] 0.31; 95% confidence interval [CI] 0.25-0.40) and 33% lower in those with scores between 3 and 4 (HR 0.67; 95% CI 0.59-0.77).
I N T R O D U C T I O N
Diabetes mellitus is prevalent worldwide, and the number of patients was estimated as 382 million in 2013 and expected to rise to 592 million by 2035 [1] . In Taiwan, $7% of the total population (about 1.6 million) had diabetes in 2012, of whom $90% had type 2 diabetes. Diabetes has been among the top five leading causes of death in Taiwan for more than three decades and took up $11.5% of the total healthcare expenditures in recent years [2] . In addition, diabetes is associated with two to four times the risk of cardiovascular disease, and is the leading cause of retinopathy and kidney disease [3, 4] .
Studies have shown that controlling the blood glucose level well can effectively reduce the risks of macrovascular and microvascular complications, including kidney disease [5, 6] . Adherence and frequent blood glucose and lipid profile testing have also been shown to be associated with significant reduction in hospitalization for diabetes, including those for renal complications, in patients with type 2 diabetes [7] . Despite such findings, studies generally found that the provision of screening tests, including the frequencies of urine and retinal examinations as well as HbA1c and lipid tests, fell well below the American Diabetes Association (ADA) recommendations [7] .
Of the many initiatives focusing on screening and quality of care for patients with diabetes [8] [9] [10] [11] [12] [13] , one of the most important has been the Diabetes Quality Improvement Program (DQIP), which proposed a unified set of process and intermediate outcome indicators, selected under the assumption that together they can predict the above-mentioned complications [13] . Only a limited number of studies have investigated the use of both process indicators (such as the frequency of low-density lipoprotein [LDL] testing) and intermediate outcome indicators (such as LDL <130 mg/dL) combined on predicting the development of specific disease complications [14, 15] . They found a clear link between the DQIP process indicators combined with intermediate outcome indicators and macrovascular complications (cardiovascular events and mortality) [14, 15] . The DQIP cut-off of poor blood glucose control is 9.5% (80 mmol/mol) for HbA1c [13] . Recent studies, assuming stricter control of blood glucose would be more effective in reducing the risk of macrovascular complications, have chosen HbA1c <8% (64 mmol/mol) as an intermediate outcome indicator of good control according to the ADA recommendations [13] [14] [15] [16] . However, those studies did not investigate the association of the process and intermediate outcome indicators with microvascular diseases such as kidney diseases. They also encountered problems with regard to the choice of process indicators [14, 15] . The ADA recommends glucose testing at least twice a year [16] , suggesting that the greater the frequency, the better the care. However, a study in Italy which used an insurance database found that glucose testing less than once a year indicated better diabetes control [14, 15] . In addition, those studies followed up long-term outcome on an average of 28 months only [14, 15] , and the relatively short follow-up may not be sufficient to allow a robust estimate of the impact of the scores on microvascular outcomes.
On the basis of previous studies, we constructed a score that included process indicators, intermediate outcome indicators, and comorbidity of hypertension. We tapped patient medical records and their national health insurance claim records to study the association between the score and the development of chronic kidney disease (CKD). In this study, we returned to the use of ADA-recommended frequencies of testing as indicators of care quality and extended the follow-up period. We also used the ADA criterion of LDL <100 mg/dL for good lipid control as one of the intermediate outcome indicators instead of the 130 mg/dL cut-off used by the previous studies and DQIP [13] [14] [15] .
M A T E R I A L S A N D M E T H O D S

Study population
We performed a retrospective cohort study in patients who were treated for type 2 diabetes at a medical center in Southern Taiwan and covered by Taiwan's National Health Insurance program. The program was launched on 1 March 1995 and covered 98% of Taiwan's residents in 2007; it reached a 99% coverage rate in 2014. A large computerized database, known as the Longitudinal Cohort of Diabetes Patients Database (LHDB), was derived from data collected by the Bureau of National Health Insurance and maintained by the Taiwan's National Health Research Institute. The LHDB contains registration information and all the claims data of 120 000 patients randomly sampled each year from those who were diagnosed with incident diabetes (by International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] code 250, A181 or 648.0) since the year 1999. The inclusion criteria are having at least (i) one hospitalization for diabetes or with prescription of diabetes medication during hospitalization, (ii) two outpatient visits for diabetes within 1 year, or (iii) one outpatient visit for diabetes together with at least one prescription of diabetes medication within 1 year. The year of the first diabetes claim was defined as the incident year, and all patients' claims were traced back to 1997.
Data collection
We obtained LHDB in 2013 and followed all the patients until 2011, regardless of the incident year. We excluded patients who were diagnosed as cases of type 1 diabetes, gestational diabetes mellitus, or CKD prior to the diagnosis of diabetes. In addition, we exluded those who were below 20 years of age, without information on sex, or followed up for <3 years ( Figure 1 ). From patients with type 2 diabetes who were treated in the medical center, we identified incident cases diagnosed between July 1999 and December 2003 from LHDB and obtained their medical records in the medical center through matching the outpatient claim date, ICD-9-CM code, and date of birth. On each patient, we retrieved medical records until the end of 2011 ( Figure 1 ). In order to preserve patient confidentiality, the medical center removed individual identifying information from medical records before the records were released to the investigators. This study was approved by the Ethics Committees of the Chi Mei Medical Center.
Quality-of-care score
We developed a summary measure of quality of care to study the association between quality of care and the development of CKD (Table 1) . While risk prediction can help in assessing the quality of care, in many cases, some of the factors that contribute to the risk may not be modifiable, such as age and sex, and thus cannot be used for assessing the quality of care. Since process variables are always modifiable and some intermediate outcomes are also modifiable, we adopted process and intermediate outcome indicators in constructing the score. The indicators were selected on the basis of a scoring system used in previous studies [14, 15] , which included three intermediate outcome indicators (LDL <130 mg/dL, blood pressure [BP] <140/90 mmHg and HbA1c <8.0% [64 mmol/mol]), four process indicators (frequencies of HbA1c lipid profile, and urine testing and BP measurement) and comorbidity of microalbuminuria. Although BP is measured on a routine basis at the Chi Mei Medical Center, Taiwan's National Health Insurance does not pay for BP measurement and thus LHDB does not contain the information on the frequency of BP measurement at other hospitals. Therefore, we omitted the frequency of BP measurement from the process indicators but added comorbidity of hypertension as an indicator. In patients with comorbidity of hypertension, however, when the BP is within the desired range (<130/80 mmHg), a negative score is assigned to the comorbidity of hypertension item. Because the most recent ADA guidelines include frequencies of foot and retinal examinations, we added these two items to process indicators. Nonetheless, because LHDB does not contain the information on microalbuminuria, we omitted the comorbidity of microalbuminuria item. We obtained data on the process indicators and comorbidity of hypertension from the LHDB and determined intermediate outcome indicators on the basis of the medical records retrieved from the medical center, because the LHDB does not contain test results. These process and intermediate outcome indicators had been adopted by other initiatives, including the DQIP [13] .
We developed the quality-of-care score (Table 1) on the basis of the scoring systems used in previous studies [14, 15] and assigned values using the same proportions accordingly, so that we can make straightforward comparisons. For lipid and glucose control, we assigned a score of 2 if both the process and the intermediate outcome indicator targets were met, a score of 1 if either the process or the intermediate outcome indicator target was met, and 0 if neither were met. For the other measures (frequencies of urine, foot and retinal examinations), one score was assigned on the basis of the data in the 3-year period prior to the censor date, 1 if target was met and 0 if not met. For BP, good BP control or a patient without comorbidity of hypertension during the study period was assigned a score of 1. If data were missing for a specific parameter, a value of 0 was assigned.
The score was not entirely the same as those used in the previous studies. We modified cut-off values according to the most recent ADA guidelines: 100 versus 130 mg/dL for LDL, 130 versus 140 mmHg for systolic BP and 80 versus 90 mmHg for diastolic BP. Likewise, we modified the scoring for frequencies of process indicators: !2 versus <1/year for HbA1c and !1 versus <1/year for lipid profile and urine. Furthermore, we included the frequencies of foot and retinal examinations (!1/year) as process indicators. While the previous system used 5-point increments to assign the scores, we used 1-point increments to make the calculation of scores easier. Accordingly, the quality-of-care score ranged between 0 and 8 in this study, whereas it ranged between 0 and 40 in the previous system. In both systems, the higher the score, the better the quality of care. 
The event/censoring date
We defined CKD by ICD-9-CM diagnostic codes. As suggested by previous studies [17, 18] , we identified the date as the event date when a related ICD-9-CM diagnostic code was listed on outpatient claims for the second time or listed on inpatient claims for the first time. For patients who did not have a CKD event and were still alive at the end of the study period, we assigned 31 December 2011 as the censoring date.
Statistical analysis
We used one-way analysis of variance (ANOVA) to evaluate the differences in continuous variables and Chi-square tests to evaluate those in categorical variables. Probabilities of CKD events were calculated using the Kaplan-Meier method. For comparing CKD event-free probabilities among different score groups, we used the Breslow test. We used Cox proportional hazard regressions to evaluate the associations between the quality of care and CKD. Covariates studied in the Cox models included age, sex, medication type, medication adherence, Diabetes Complications Severity Index (DCSI) [20] , and past history of hypertension or dyslipidemia. We performed all statistical analyses using SAS software, Version 9.2 (SAS, Cary, NC, USA) and performed all statistical tests at a two-sided significant level of 0.05.
Because there were some missing values, we conducted a sensitivity analysis by repeating variable selection and score estimation on a data set that included only patients with complete data. There are two reasons that could cause a missing values. One is that the physician did not order the test/examination or the patients did not receive it. The other, which occurs rarely, is that the patient might receive the test/examination somewhere other than the medical center. However, because of the facts that BP can fluctuate remarkably and that foot examination is not regularly performed in Taiwan, these two items were taken out of the summary score in the sensitivity analysis. In other words, patients who had missing data on these two items could still be included in the analysis.
R E S U L T S
We enrolled 4754 diabetic patients, including 2605 (54.8%) men and 2149 (45.2%) women ( Table 2 ). The mean age at diagnosis was 55.3 years old, and more than half of the patients were diagnosed between 40 and 65 years of age (67.1%). Most of the patients (70.4%) took oral anti-diabetic drugs (OAD) only, and the number of patients who received insulin injections only was similar to the number who received both OAD and insulin treatment during the study period. On the basis of pharmacy refill records, we defined a good adherence as a ratio between 90% and 110% [19] and found that 22.9% of the patients had good adherence. Using the DCSI [20] , we divided the patients into six groups, from 0 to !5, and found 69.3% of them were in the first group and only 0.2% were in the last. During the year prior to diagnosis, 24.4% of the patients had hypertension, 3.5% had dyslipidemia, and 5.3% had both.
Around 65.8% of the patients had a quality-of-care score 2, and only 11.6% had a score !5. In comparison with patients in the other two score groups, patients in the lowest score group were older, predominantly male, and more likely to be treated with insulin only. They also had worse adherence to treatment and a shorter diabetes history ( Table 2) .
We followed up the patients for a mean of 9.1 years, and more than 90% of the patients were followed up for more than 5 years. During the follow-up, 1407 (29.6%) patients developed CKD events, and the incidence rate was related to the score: 38.76 per 1000 person-years in patients with a score of 2, 27.01 per 1000 person-years in those with a score between 3 and 4, and 13.10 per 1000 person-years in those with a score of !5. Kaplan-Meier curves show that a score of 2 was associated with a higher likelihood of developing a CKD event (P for log-rank test <0.001).
Cox proportion hazard models showed that the risk of developing a CKD event was 69% lower in patients with a score of !5 (hazard ratio [HR] 0.31; 95% confidence interval [CI] 0.25-0.39) and 34% lower in those with a score between 3 and 4 (HR 0.66; 95% CI 0.58-0.76), when compared with those with a score of 2 (Table 3) . Patients !65 years old had a 72% increase in the risk (HR 1.72; 95% CI 1.40-2.12) compared with those 40 years of age. When we divided patients into three medication adherence groups: poor (<90%), good (between 90% and 110%) and supernormal (!110%), we found that supernormal adherence was associated with a higher risk of developing a CKD event (HR 1.32; 95% CI 1.03-1.70) when compared with good adherence.
After adjusting for age, sex, type of diabetes medications, adherence, DCSI, and past history of hypertension or dyslipidemia, we found the risk of developing a CKD event was 69% lower in patients with a score !5 (adjusted HR [AHR] 0.31; 95% CI 0.25-0.40) and 33% lower in those with a score between 3 and 4 (AHR 0.67; 95% CI 0.59-0.77) when compared with those with a score 2 ( Table 3) . Other independent predictors identified in this study included !65 years of age (AHR 1.62; 95% CI 1.31-2.02, compared with those with 40 years of age) and supernormal adherence to medication (AHR 1.34; 95% CI 1.04-1.72 when compared with good adherence).
When we applied the scoring system proposed by another research team [14, 15] , we did not see the risk of developing a CKD event decrease as the score increased (Table 4 ). In contrast, using the scoring system we developed, we observed similar risks from 0 to 1 and decreased risks afterward with a doseresponse relationship until 8, when the number of patients was only nine and thus the risk estimate became too unstable.
The sensitivity analysis showed the risk significantly decreased with a dose-response relationship as observed in the main analysis (Table 4) .
D I S C U S S I O N
Diabetes is a disease that is strongly associated with both macrovascular (coronary artery disease, peripheral arterial disease, stroke, etc.) and microvascular complications (nephropathy, neuropathy, retinopathy, etc.), affecting various organs and tissues in approximately one-third to one-half of the patients [21] . The components of metabolic syndrome, along with the independent risk factors for diabetes, can act both independently, cumulatively, and interactively over time to increase the risk of Quality of diabetic care and CKD events CKD [22] . Therefore, diabetes is a complex chronic progressive metabolic disorder requiring ongoing medical care with multifactorial risk-reduction strategies extending beyond glycemic control. All the six indicators (HbA1c, BP, LDL, urine, foot and retinal examination) adopted in our scoring system are also included the criteria used in the pay for performance (P4P) program for diabetes supported by the Taiwan government [23] . The P4P for diabetes gives physicians financial incentive to enroll diabetic patients, with the aim of improving the quality of care. Patients who join the P4P program are more likely to receive diabetes-related testing than those who do not [24] . A population-based longitudinal study that observed the longterm effects of the P4P program in Taiwan showed that the program was cost-effective [24] . Our study confirmed that good quality of care for patients with diabetes was associated with a reduction in the risk of developing a CKD event and that the quality-of-care score we developed can be a good indicator of the risk for prediction and thus for surveillance as well.
Because of the huge manpower and financial burden, many nations have intensified their efforts to deal with diabetes. However, the available data on its clinical care have considerable gaps across countries [25] . Outcomes of diabetic care have been shown to vary substantially among different health care systems from different countries [25] . The previous AMD-QUASAR study [14] in Italy substantially reproduces the body of evidence reported by the QuED study [15] , confirming the validity and applicability of the modified DQIP instrument, which could effectively predict the risk of macrovascular disease [14, 15] . Because the mean quality score widely differed among centers, the study estimated the intra-class correlation coefficient (ICC) using the score as dependent variable to evaluate the extent to which the score varies among centers when compared with within-center variation, taking patient case-mix into account [14] . In contrast, our study has the advantage of obtaining all the values of laboratory parameters from the same medical center and thus applying real data to the calculation of the scores directly. The parameters in our scoring system adhere closely to ADA recommendations of diabetic care. We have tried to apply the scoring system proposed by previous studies [14, 15] to our participants and found the score to have a poor dose-response relationship with CKD, indicating that the scoring system cannot be used for predicting CKD in a different country. Therefore, the new scoring system we proposed is better than the previous one for this purpose, in Taiwan at least. This finding suggests that indicators of good diabetic care may vary across nations, and the same process indicator or intermediate outcome indicator may have different implications in different countries. For example, frequent laboratory testing may be an indicator of poor care quality in Italy [14, 15] but indicates good care quality in Taiwan, compatible with the ADA guidelines. The incidence and prevalence of CKD in diabetic patients varies across different studies depending on the population characteristics and definition of disease. While a study in the UK found that the prevalence rate of CKD at Stages 3-5 in diabetic patients was 27.5% [26] , another UK study found the rate was 31% in patients with diabetes and 6.9% in those without diabetes [27] . After a 15-year period, the UK Prospective Diabetes Study (UKPDS) [6] , a study of patients with type 2 diabetes 25-65 years of age, showed that 38% of the patients developed albuminuria and 29% of them developed renal impairment as defined by a reduced estimated glomerular filtration rate (eGFR) or a doubling in serum creatinine [28] . In another report of UKPDS, the incidence rate of microalbuminuria was 2% per year, and the 10-year period prevalence rate after diagnosis was 25% [29, 30] . In our study, the cumulative incidence rate of CKD was 29.6% after a mean follow-up of 9.06 years.
In this study, we used pharmacy refill records to determine the adherence of diabetic medication. Claims-based measures of medication adherence have been shown to be associated with health outcomes in patients with diabetes [31] . We found that patients with supernormal adherence (!110%) had an increased risk of CKD (AHR 1.34; 95% CI 1.04-1.72), which is compatible with the finding in a cohort study that patients who were overpersistent in their use of hypoglycemic drug (adherence >110%) were less likely to achieve the HbA1c goal [30] . The researchers believed that these patients were most likely sicker than the others because they had higher baseline HbA1c, more comorbidities and more hospitalizations [32] but did not evaluate the extent that supranormal adherence reflects non-compliance with treatment. In this study, we were unable to address this issue, either, because the National Health Insurance of Taiwan does not limit the number of refills and thus does not ask patients the reasons for over-refills.
Even with a large number of participants and long periods of follow-up, our study has some limitations. First, besides the indicators we used to calculate the score, lifestyle characteristics such as diet, smoking, and exercise can affect the outcome, especially in long-term follow-up. Nonetheless, the previous studies that In order to compare the performance of our scoring system with that of a well-established system, we used 5-point increments to assign the scores. *P < 0.05; **P < 0.01; ***P < 0.001.
tried to develop a scoring system did not take these factors into consideration, either. Furthermore, whereas we could not adjust for the effect of smoking directly, because the prevalence of smoking in Taiwanese females is very low, e.g. 4.4% in 2011 [33] , it has been largely adjusted when the analyses were adjusted for sex. Second, our study obtained medical records from a medical center, and some of the values needed to calculate the score were missing. However, in the sensitivity analysis that included only patients with complete data, the conclusions are the same as those from the analyses using the whole study population. Third, because our study obtained medical records from a medical center in Taiwan where there is a national health insurance program and a high density of medical care facilities, further studies are needed to evaluate whether the findings can be generalized to diabetic patients in countries where medical care is less affordable and accessible. Fourth, we determined the occurrence of CKD on the basis of LHDB, which does not contain laboratory test results and therefore could not define CKD in greater details such as the occurrence of microalbuminuria, a defined decrease in eGFR, or a defined stage of CKD. Fifth, because the main purpose of this study is to develop a new scoring system on the basis of the previous one and compare their performance in predicting the risk of CKD, we did not consider making changes to the indicators unless it was absolutely necessary. Therefore, other modifications that might improve the performance of the score were not evaluated in this study, which calls for further studies.
In conclusion, findings in our study support the use of the new quality-of-care score in assessing the quality of care of diabetic patients with CKD events as the outcome indicators. The score can help identify patients with suboptimal care and pinpoint which aspects of care need to be improved. We found the risk of CKD significantly decreased as the score increased, and therefore interventions targeting at each indicator should be adapted in order to slow the progression of diabetic nephropathy and other complications as well. These include both receipt of processes of care tests and combination therapy targeting hyperglycemia, hypertension, and dyslipidemia. The score we proposed is easy and convenient to calculate, and can be used to compare performance across centers and evaluate quality improvement initiatives. With different healthcare systems, different countries may make modifications to the scoring system for better applications.
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